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Toxicityrodegenerative disorders that include Creutzfeldt–Jakob disease in humans and
bovine spongiform encephalopathy in animals. They are unique in terms of their biology because they are
caused by the conformational re-arrangement of a normal host-encoded prion protein, PrPC, to an abnormal
infectious isoform, PrPSc. Currently the precise mechanism behind prion-mediated neurodegeneration
remains unclear. It is hypothesised than an unknown toxic gain of function of PrPSc, or an intermediate
oligomeric form, underlies neuronal death. Increasing evidence suggests a role for the ubiquitin proteasome
system (UPS) in prion disease. Both wild-type PrPC and disease-associated PrP isoforms accumulate in cells
after proteasome inhibition leading to increased cell death, and abnormal β-sheet-rich PrP isoforms have
been shown to inhibit the catalytic activity of the proteasome. Here we review potential interactions
between prions and the proteasome outlining how the UPS may be implicated in prion-mediated
neurodegeneration.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Prion diseases, or transmissible spongiform encephalopathies
(TSEs), are a family of fatal neurodegenerative disorders (Table 1).
They affect both humans and animals, and can be transmitted
within or between animal species by inoculation or dietary
exposure [1]. Despite their relative rarity–it is estimated that they
affect one person per million worldwide annually–they remain in
the spotlight due to the unique biology of the transmissible agent.
Their pathogenesis is associated with a conformational re-arrange-
ment of a normal cellular prion protein, PrPC, to an abnormal
isoform, PrPSc (Sc for scrapie) [2]. Prion diseases share the
following histopathological hallmarks: spongiform vacuolation,
severe neuronal loss, astrocytic and microglial proliferation, and
accumulation of the disease-associated isoform of the prion protein
in the brain, sometimes with the formation of amyloid deposits.
Currently, the exact cause of prion-mediated neurodegeneration
remains unclear and a major gap exists in the understanding of
how the conversion of PrPC to PrPSc ultimately kills neurons. Here
we give an overview of the biology of prion disease, highlighting
the mechanisms by which prions might cause neurotoxicity and
considering the role of cellular protein degradation systems such as
the ubiquitin proteasome system (UPS) in prion-mediated cellular
neurodegeneration.+44 207 676 2180.
rizi).
l rights reserved.1.1. Prion diseases in humans and animals
The prototypic prion disease is scrapie, a common disease
affecting sheep and goats (Table 1). Other mammalian prion
diseases include transmissible mink encephalopathy, chronic wast-
ing disease of deer and elk, and bovine spongiform encephalopathy
(BSE) in cattle. The latter, which is often referred to as ‘mad cow
disease’, emerged in the UK in 1986, causing a major epidemic
thought to have started due to contaminated feed containing
ruminant-derived protein [3].
Human prion diseases include Creutzfeldt–Jakob disease (CJD),
Gerstmann–Sträussler–Scheinker disease (GSS), fatal familial insom-
nia (FFI) and kuru [4,5] (Table 1). Clinical features comprise rapidly
progressive dementia accompanied by cerebellar ataxia, myoclonus
and pyramidal or extrapyramidal disturbances. Prion diseases are
unique in that they may arise spontaneously, be genetically inherited,
or acquired via infection. Approximately 85% of CJD cases occur
sporadically with no known cause, whereas 15% of human prion
diseases (including GSS, familial CJD and FFI) represent autosomal
dominantly inherited conditions associated with mutations in the
prion protein gene, PRNP [6]. Acquired forms of the disease include
iatrogenic CJD resulting from accidental medical exposure to prions,
and kuru, which emerged as an epidemic in the Eastern Highlands of
Papua New Guinea and affected mostly women and children involved
in ritual cannibalistic feasts [7]. Variant CJD (vCJD), a new acquired
humanprion disease, ﬁrst emerged in themid 1990's in the UK [8] and
has affected ∼170 individuals (http://www.cjd.ed.ac.uk/ﬁgures.htm).
Suspicions of a link between vCJD and BSE were raised because they
arose at the same time. Clinical, neuropathological and molecular
Table 1
Prion diseases of humans and animals
Prion disease Host Aetiology
Scrapie Sheep and goats Ingestion, horizontal
transmission
Transmissible mink
encephalopathy
Mink Ingestion
Chronic wasting
disease
Mule deer,
white-tailed deer,
Rocky Mountain elk
and moose
Ingestion, horizontal
transmission
Bovine spongiform
encephalopathy
Cattle
Feline spongiform
encephalopathy
Domestic and
captive wild cats
Acquired by ingestion of
BSE-contaminated meat
Exotic ungulate
encephalopathy
Nyala, oryx and
greater kudu
Sporadic CJD Human Unknown
Iatrogenic CJD Human Acquired by accidental
exposure from medical
contact with human
prion-contaminated
neurosurgical instruments,
tissue grafts and pituitary
hormones derived from
human cadavers
Familial CJD Human
Fatal familial
insomnia
Human Inherited; all associated with
PRNP-coding mutations
Gerstmann–Sträussler–
Scheinker disease
Human
Variant CJD Human Environmental exposure
possibly via ingestion of
BSE-contaminated meat.
Three blood transfusion-
associated cases (from
vCJD donors)
Kuru Human Exposure via endocannibalism
in a small area of Papua
New Guinea
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as BSE [9–11]. Although the number of conﬁrmed cases is small, the
actualﬁgure of subclinically infected individuals remains unknown. All
clinical cases of vCJD to date have occurred in individuals homogygous
for methionine at codon 129 of the PRNP gene. Prion diseases are
associated with long, clinically silent incubation periods, which in
human-to-human transmission, such as seen in kuru, can exceed
50 years [7]. As human infection with BSE involves cross-species
transmission, it may confer a substantial prolongation of incubation
time and thus vCJD still poses a serious threat to public health. This is
highlighted by the efﬁcient secondary transmission of infection via
blood transfusion [12–14].
1.2. Protein-only hypothesis
The nature of the causative agent in prion disease has been the
focus of intense research. Grifﬁth ﬁrst proposed that transmission of
scrapie was via a protein-only mechanism [15], as no experimental
data supported the notion that a nucleic acid is associated with prion
infection. For example, the transmissible agent is resistant to
procedures that modify nucleic acids, such as ultraviolet and ionizing
radiation [2]. In 1982, progressive enrichment of scrapie-infected
hamster brain homogenates for infectivity led to the isolation of a
protease-resistant protein, designated the prion protein (PrP) [16]. The
term ‘prion’ was ﬁrst coined by Stanley Prusiner to distinguish the
infectious agent in prion disease as a pathogen from bacteria and
viruses, and refers to a ‘small, proteinaceous infectious particle that
resists inactivation by procedures which modify nucleic acids' [2].
Following the puriﬁcation of the protein, the gene encoding PrP was
identiﬁed [17]. The normal product of the prion protein gene is a 33–35 kDa protein called the cellular prion protein (PrPC). The disease-
associated isoform of the prion protein, PrPSc, is post-translationally
derived from PrPC [18,19] and has increased β-sheet content [20]. PrPC
and PrPSc do not differ in amino acid sequence and there are no
antibodies that clearly discriminate between these two isoforms. PrPSc
is currently distinguished from PrPC by its partial proteinase K (PK)
resistance and detergent insolubility (Fig. 1A). Despite worldwide
research, the exact nature of the infectious agent is still unknown and
there is evidence both for and against PrPSc as the infectious agent.
Even though a form of PrP may be infectious, there is some evidence
that this form may not be PrPSc. This is highlighted by the lack of
correlation between infectivity and PrPSc levels [21,22] as well as by
the existence of PK-sensitive forms of PrPSc [23–29].
The protein-only hypothesis, which postulates that prion propaga-
tion results from a change in PrP conformation whereby PrPSc recruits
endogenous PrPC in order to replicate, is now well established. Some
of the strongest supporting evidence comes from ﬁndings that
inherited prion diseases are linked to mutations in the PRNP gene
[1], indicating that a genetic disease may be able to propagate in an
infectious way. Another important line of evidence comes from PrPC
knockout mice, which are resistant to scrapie prions [30]. Moreover,
infectious prions have been shown to consist mainly or exclusively of
PrPSc, as indicated by a large body of experimental data. Most notably,
synthetic prions that polymerise into ﬁbrils in vitro have been shown
to be infectious in vivo [31]. Similarly, the in vitro generation of prions
by the protein-misfolding cyclic ampliﬁcation assay (PMCA), shows
that synthetic prions share similar biochemical characteristics to the
disease-associated isoform of the prion protein and when inoculated
into mice lead to a scrapie-like disease [32]. However, the existence of
multiple prion isolates, or strains, which are characterised by
differences in incubation period, biochemical properties, neuropatho-
logical and clinical features, have posed problems for the protein-only
model for prion propagation. These differences have been previously
attributed to different conformation or aggregation states of PrPSc,
each having distinct abilities to catalyse the conversion process
[23,33]. Recently, however, a general hypothetical model of prion
strains and their pathogenicity has been proposed that explains how
multiple prion strains could exist within the protein-only hypothesis
criteria [34]. Alternative possibilities such as the ‘uniﬁed hypothesis’,
put forward by Charles Weissmann, argue that although infectivity
depends only on the protein, strain characteristics could be encoded
by a small nucleic acid [35]. A protein-only based mechanism of
inheritance may have wider relevance in biology and these mechan-
isms have been extensively investigated in yeast and fungi [36–38].
1.3. Prion protein
1.3.1. Structure and function
PrPC is a highly conserved, approximately 250 amino acid
glycoprotein, abundant in neuronal and glial cells of the central
nervous system (Fig. 1B). It has two N-glycosylation sites and is
glycosylphosphatidylinositol (GPI)-anchored to the plasmamembrane
[39]. Its C-terminal domain is folded largely into α-helices stabilised
by a single disulphide bond and NMR spectroscopy shows it is
monomeric [40]. The N-terminus contains an octapeptide repeat
regionwith tight binding sites for Cu2+ [41]. PrPC is glycosylated in the
ER after the removal of an N-terminal signal peptide [42] (Fig. 1B). The
GPI anchor is attached after cleavage of a second signal peptide at the
C-terminus. The protein is then trafﬁcked via the Golgi to the cell
surface, where it is internalised in clathrin-coated pits and endocy-
tosed for recycling [43,44]. The function of PrPC remains unknown,
although a number of roles have been proposed due to its remarkable
conservation between species [45]. Loss of PrPC expression shows no
overt phenotype in both embryonic PrPC-null mice and adult-onset
knockout models [46,47]. However, these embryonic PrPC-null mice
develop abnormalities in synaptic physiology, circadian rhythm and
Fig. 1. Prion protein (A) Immunoblot analysis of normal mouse brain (CD1) and prion-infected mouse brain (RML) before and after proteinase K (PK) treatment. PrPC is completely
digested by PK treatment in both normal and RML mouse brain. In contrast, PrPSc present in prion-infected mouse brain is partially resistant to PK treatment, which leads to the
generation of amino-terminal-truncated fragments of diglycosylated, monoglycosylated or non-glycosylated PrP. (B) A schematic of the normal cellular murine prion protein.
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localisation and on PrPC-interacting molecules, and include cell
adhesion [50–52], synaptogenesis [53], signalling [54], copper home-
ostasis [55], and neuroprotection [56–59]. PrPC has also been
implicated in the self-renewal of hematopoietic stem cells during
serial transplantation [60]. Recently, links between Alzheimer's
disease (AD) and prion disease have been proposed as PrPC was
shown to regulate neurotoxic Aβ production by inhibiting β-secretase
cleavage of the amyloid precursor protein [61].
1.3.2. Prion-mediated toxicity
Prion-mediated cell death appears to be caused via apoptosis
[62,63], but the exact mechanism is poorly understood. A full
overview of possible pathways of prion-mediated neurotoxicity is
beyond the scope of this review but has been recently reviewed
[64–66]. PrPC is essential for the development of prion disease, but
loss of function of PrPC is unlikely to be the cause of pathology
because neither embryonic nor adult knockout of PrPC results in
neurodegeneration [46,47]. It is widely hypothesised that an
unknown toxic gain of function of PrPSc, or its precursor, is more
likely to underlie cell death. Studies have suggested that both full-
length PrPSc [67] and shorter PrP peptides are toxic to cells in vitro
[68], but their relevance to in vivo pathogenesis is under debate.
There is strong evidence that PrPSc itself may not be the toxic entity,
but instead a toxic oligomeric PrP intermediate species may be
produced during prion conversion [34]. For example, PrPC-null
tissue remains healthy and free of pathology when exposed to PrPSc
[69,70], and there is no direct correlation between neuronal loss and
PrPSc plaques in CJD brains [71]. In addition, prion diseases in which
PrPSc is barely detectable have also been described [21,72,73], and
subclinical infection where high levels of PrPSc accumulate in the
absence of clinical symptoms are also recognised [74–77]. Prion-
infected mice expressing PrPC without a GPI anchor produce
infectious prions, accumulate extracellular PrP amyloid plaques,
but do not succumb to disease [78]. It has been suggested that PrPSc
needs to interact with cell surface PrPC to exert a neurotoxic effect
via aberrant signalling cascades [64,79,80]. An alternative explana-
tion for these experimental observations is that accumulation of
high intracellular levels of disease-associated PrP or an intermediate
species within neurons themselves is required for cytotoxicity. Other
suggested neurotoxic mechanisms relate to altered PrPC trafﬁcking;
PrPC can assume two different transmembrane topologies (CtmPrP-C
transmembrane PrP with an extracellular C-terminus and NtmPrP-N
transmembrane PrP with an extracellular N-terminus) one of which,
CtmPrP, has been shown to confer severe neurodegeneration in mice
with features typical of prion disease [81].2. Prions and the proteasome
2.1. Ubiquitin proteasome system
The UPS is the primary cellular quality control system in eukaryotic
cells for selecting and degrading proteins that are either incomplete,
missense, or misfolded, and that could potentially form toxic
aggregates [82]. UPS-mediated protein degradation is a highly
complex process [83] regulating a number of cellular functions such
as cell division, gene expression, differentiation and development,
DNA repair, and organelle biogenesis. In this degradation system, a
polyubiquitin chain is covalently attached to the substrate, thereby
serving as a ‘degradation tag’, and substrates are degraded by the 26S
proteasome into small peptides, with free ubiquitin released for
recycling. The 26S is a large, ATP-dependent enzyme complex, resident
in both the nucleus and the cytosol of eukaryotic cells. It consists of a
20S proteolytic core and one or two 19S regulatory particles (Fig. 2A).
Access to the 20S core is controlled by the six ATPases of the 19S
particle [84]. The 20S is a hollow, barrel-shaped protein complex
composed of α and β subunits arranged in four stacked rings. These
stacked rings surround a central catalytic chamber whereby degrada-
tion proceeds without interference from the cytosol. The two α rings
form gated channels through which substrates enter and peptides exit
the 20S. The proteolytic activity of the 20S resides in its twoβ rings and
consists of three distinct catalytic activities termed β1 (caspase-like),
β2 (trypsin-like), and β5 (chymotrypsin-like) and the secondary
alcohol of the N-terminal threonine of the active β subunit acts as
the nucleophilic species [85]. Following recognition by the 19S, the
polyubiquitinated substrate docks onto the 19S particle and is
unfolded via the action of six ATPases, which then translocate the
substrate and trigger gate opening (Fig. 2B). Docking of the C-termini of
the ATPases into intersubunit pockets in the α-ring of the 20S opens
the gate in a ‘key in a lock’ fashion to allow substrate entry [86].
UPS impairment may play a role in neurodegenerative diseases,
such as AD, Parkinson's disease (PD), and Huntington's disease (HD),
which are all characterised by the accumulation of aggregated
misfolded proteins [87]. Proteasomes cannot efﬁciently degrade
aggregated protein [88] and in cell models the functional capacity of
the UPS has been shown to be impaired by protein aggregates [89]. At
present, its pathogenic role in some of these neurodegenerative
diseases is not clear. Polyglutamine pathogenesis has been reported in
the absence of signiﬁcant proteasome impairment in a spinocerebellar
ataxia 7 mouse model [90]. In an HD mouse model, there was no
detectable impairment of proteasome catalytic function [91]. Recently,
however, global changes to the ubiquitin system have been shown in
HD [92]; using a mass-spectrometry-based method it was reported
Fig. 2.Ubiquitin proteasome systemmediated degradation (A) Schematic of the 26S proteasome in Saccharomyces cerevisiae, showing the 20S proteolytic core and one 19S regulatory
particle. The 19S is made up of two subcomplexes termed lid and base, the latter consisting of six homologous members of the ATPase family (shown in red) and two larger non-
ATPase subunits (Rpn1 and Rpn2). The C-termini of the ATPases dock into intersubunit pockets in theα-rings of the proteasome and open the gate for substrate hydrolysis by the 20S
β subunits. Cross section of the β-ring reveals the positions of the caspase-like (β1), trypsin-like (β2) and chymotrypsin-like (β5) subunits (all shown in yellow). Rpn, regulatory
particle non-ATPase; Rpt, regulatory particle ATPase. (B) Schematic of UPS-mediated degradation. The 26S degrades proteins in an ATP-dependent manner. The ubiquitinated
substrate binds to the 19S where the ubiquitin chain is removed. The 19S ATPases unfold and translocate the substrate through the open gate (shown in red) and into the 20S for
proteolysis. ATP denotes adenosine triphosphate, ADP adenosine diphosphate, and Pi inorganic phosphate. B is adapted from Goldberg AL. On Prions, Proteasomes, and Mad Cows.
NEJM (2007) 357:1150–1152. Copyright© (2007) Massachusetts Medical Society. All rights reserved.
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proteasomal targetting, accumulate early in pathogenesis in both
transgenic HD mouse brains and human HD patient brain [92].
2.2. The UPS in prion disease
2.2.1. Cytosolic PrPC and the proteasome
The UPS is involved in ER-associated degradation (ERAD) where
ER-resident proteins, in unassembled or misfolded forms, undergo
retrograde transport to the cytosol, get ubiquitinated and are
normally degraded by the proteasome [93]. Both wild-type and
misfolded forms of PrPC undergo ERAD [94,95]. A pathogenic PrPC
mutant (Y145stop) associated with an inherited prion disease, GSS, isdegraded via ERAD [96], whereas another GSS-associated PrPC
mutant (Q217R), remains bound to BiP, an ER chaperone, for an
unusually long period of time before proteasomal degradation [97].
More importantly, wild-type PrPC molecules undergoing ERAD have
been shown to accumulate in the cytosol when the proteasome is
inhibited [94,95]. Yedidia et al. showed that cells treated with
proteasome inhibitors accumulated both detergent-soluble and
insoluble PrPC species, with the latter containing a protease-resistant
core and ubiquitin [94]. In a separate study, Ma and Lindquist
showed that inhibition of the proteasome in cells led to a signiﬁcant
fraction of endogenous PrPC accumulation in the cytoplasm [95]. The
authors suggest that PrPC gets to the cytoplasm via retrograde
transport. Electron microscopy of mouse brain sections shows that
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neocortex and thalamus, supporting the fact that cytosolic PrPC
occurs in vivo [98]. UPS impairment may allow the conversion of
cytosolic PrPC to an abnormal, ‘PrPSc-like’ form, with partial protease
resistance and detergent insolubility [99]. Proteasome inhibition
causes the accumulation of PrPC aggregates in the cytosol of neurons
with some PrPSc-like properties, such as self-sustaining replication
and partial PK resistance [99]. It is possible that if the quantity of
PrPC exceeds the degradative capacity of the UPS, then some PrPC
may be able to convert to a protease-resistant pathogenic form as
removal of the proteasome inhibitor does not affect the abnormal
PrP generation process once it starts [99].
The relationship between UPS inhibition, cytosolic PrPC accumula-
tion and neurotoxicity in prion disease has been investigated. Studies
indicate that cytosolic PrPC accumulation appears toxic to neurons
[66]. It has been shown that cells with higher levels of PrPC expression
are selectively killed by treatment with proteasome inhibitor [100]. In
the same study, the authors showed that unglycosylated PrPC lacking a
signal peptide and hence the ability to trafﬁc to the ER, accumulates in
the cytosol and is neurotoxic. In agreement with these ﬁndings, it has
been shown that cytosolic PrPC accumulates in cells when the function
of the PrPC signal sequence is compromised [101]. More evidence for a
toxic role of cytosolic PrPC comes from a yeast model in which it was
shown that during post-translational targeting of PrPC to the ER, PrPC
is missorted to the cytosol and interferes with cell viability [102].
Additionally, toxicity has been linked to cytosolic PrPC accumulation,
when PrPC co-aggregates with the anti-apoptotic protein Bcl-2 with
toxicity abrogated after over-expression of Hsp70 and Hsp40 [103]. In
vivo, mice expressing a PrPC mutant lacking the N-terminal ER
targeting signal (cytoPrP) develop normally, but are severely ataxic,
with cerebellar degeneration and gliosis; they also accumulate an
insoluble PrPC form [100].
In spite of the experiments described above, the neurotoxic
nature of cytosolic PrPC in prion pathogenesis is under debate.
Cytosolic PrPC accumulation in human primary neurons treated with
proteasome inhibitors has been reported and is not toxic;
paradoxically it protects against Bax-mediated cell death [58].
Importantly, there have been observations that neither mutant nor
wild-type PrPC undergo retrograde transport prior to proteasome
degradation in various cell models [104,105]. Furthermore, it has
been argued that cytosolic PrPC accumulation may be a result of
elevated levels of PrPC expression from the cytomegalovirus (CMV)
promoter used in many of the experiments. Drisaldi et al. show that
proteasome inhibition results in the accumulation of unglycosylated
cytosolic PrPC in cells over-expressing PrPC under the CMV
promoter, but not in untransfected cells or Tg mice-derived primary
neurons, which express PrPC from the endogenous promoter [104].
Similarly, Fioriti et al. show that UPS inhibition in transfected cells
expressing mouse mutant PrPC homologues associated with inher-
ited prion diseases causes accumulation of an unglycosylated,
aggregated form of PrPC in transfected cells that is not toxic [105].
In agreement with previous ﬁndings [104], the authors show that
elevated PrPC expression leads to cytosolic PrPC accumulation and
suggest this is due to impaired degradation of abortively translo-
cated, signal peptide-bearing molecules synthesised from the CMV
promoter.
Moreover, the occurrence of PrPC retrograde transport has been
challenged as antibodies against the signal peptide show that PrPC
accumulates in the cytosol as a result of failed translocation into the
ER. In vivo, accumulation of unglycosylated cytosolic PrPC did not
cause any overt phenotype in aged, gene-targeted mice [106]. These
lines of evidence suggest that some PrPC undergoes ERAD, but this
proportion is most likely rapidly broken down and is a short lived
species [94]. Despite conﬂicting data, aberrant PrPC trafﬁcking to the
cytosol, which does appear to occur via ERAD [94,95], may play a role
in prion pathogenesis but as yet not fully deﬁned.2.2.2. UPS inhibition and PrPSc aggresomes
A correlation between elevated levels of ubiquitin protein
conjugates and reduced proteasome function in prion-infected
mouse brain has been reported [107]. Therefore, proteasome impair-
ment may indeed be important in prion pathogenesis. Large,
intracellular, pericentrosomal structures termed aggresomes are
thought to be a precise response when cells try to cope with increased
levels of misfolded and aggregated proteins, evidenced by the active
recruitment of proteasome components and molecular chaperones to
these aggregates [108]. PrPC and PrPSc aggresome formation has been
reported in prion disease models in vitro [109–113]. Wild-type cells
treated with cyclosporine A, an immunosuppressant, accumulate
proteasome-resistant, ‘prion-like’ PrP species in aggresomes [109].
When the proteasome is inhibited pathogenic PrPC mutants have also
been reported to accumulate in aggresomes [109]. In vitro, GFP-tagged
PrP mutants associated with familial prion disease accumulated in
cytosolic, aggresome-like structures after proteasome inhibition,
whereas GFP-tagged wild-type PrPC did not [110]. Moreover, the
formation of cytosolic PrPC aggresomes after transient cytoplasmic
PrPC expression appears to be toxic in both neuronal and non-
neuronal cells [111]. Recently, cytoplasmic PrPC aggresomes were
shown to induce cell death in various cell models bymodifying the cell
stress response via the activation of the RNA-dependent protein
kinase and the induction of poly(A)+RNA aggregation [112]. In 2005,
we reported that mouse prion-infected neuronal cell lines are more
susceptible to cell death after proteasome inhibition [113]. In our cell
system we used mild levels of proteasome inhibition, which is
suggested to mimic the loss of proteasome activity associated with
either the ageing process [114,115] or thatmay be seen in prion disease
in vivo [107,114–116]. In our study, after mild proteasome inhibition,
prion-infected cells formed cytosolic aggresomes containing PrPSc,
hsp70, ubiquitin and proteasome subunits [113]. Our work showed
that PrPSc aggresome formation was temporally associated with
caspase 3 and 8 activation, and subsequent apoptosis in prion-
infected cells [113]. In our cell system, PrPSc aggresome formation and
subsequent cell death were abrogated after treatment with micro-
tubule inhibitors which prevented aggresome formation [113]. In our
study, we found evidence for PrPSc aggresome-like structures in prion-
infected mouse brain [113]. Granular deposits of disease-related PrP
have been previously reported in neuronal perikarya from postmor-
tem sporadic CJD cases, suggesting intra-neuronal prion aggregates
may play a role in disease pathogenesis [117].
At present, PrPSc trafﬁcking is poorly deﬁned due to the lack of
PrPSc-speciﬁc antibodies and hence the way PrPSc may enter the
cytoplasm to form aggresomes has not been established [42].
Possibilities include retrotranslocation from the ER [94,95] or via
endolysosomal membrane destabilisation and leakage into the
cytosol, as described for Aβ1–42 [118]. UPS impairment due to the
aging process or during prion infection in vivo [116], may allow for
PrPSc accumulation into toxic aggresomes. A key question is whether
this accumulation is accompanied by concomitant buildup of a
distinct neurotoxic intermediate oligomeric species.
2.3. PrP oligomers and the UPS
There is growing consensus that preﬁbrillar soluble protein
aggregates, rather than insoluble ﬁbrils, may in fact be the toxic species
in neurodegenerative disease [119]. Nonetheless, this theory is currently
limited due to the lack of a precise physical deﬁnition for these
preﬁbrillar soluble protein aggregates, or ‘oligomers’. The molecular
mechanisms of prion protein misfolding, and the role of intermediate
states when the prion protein transits from an α-helical to a β-sheet-
rich structure has not yet been possible to deﬁne. Structural studies of
recombinant PrP molecules demonstrate that the protease-resistant
core can distinctly fold not only into amyloid ﬁbrils, but also into β-
sheet-rich oligomers [120–122]. Although the size of such β-oligomers
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their structure [120,123–125]. The proposed oligomeric precursor of
PrPSc could have similar properties to preﬁbrillar species seen in AD
[126]. Prion oligomers have been implicated to play a role in toxicity and
infectivity in prion disease [127,128].
In our most recent work, we found evidence that misfolded PrP
triggers a potential neurotoxic mechanism that may explain why
extracellular PrPSc itself is not toxic [116]. We demonstrated a
signiﬁcant loss of chymotrypsin-like (β5) and caspase-like (β1)
proteolytic activity in prion-infected cells and prion-infected mouse
brain, with a lesser effect on trypsin-like (β2) activity. We also
presented evidence for inhibition of the catalytic β-subunits of the
26S proteasome in vitro by recombinant β-sheet-rich forms of PrPFig. 3. Disease-associated prion protein oligomers inhibit the 26S proteasome (A) The GFP-pr
neuroblastoma (UbG76V-GFP) cells or proteasome inhibitor-treated (50 μM lactacystin) N2aP
treated with anti-PrP antibody. (B) Immunohistochemical studies of GFP-proteasome repo
prion strain (22L) (top) or normal brain homogenate (NL) (middle), and nontransgenic litterm
sections through the hippocampus (H), third ventricle (V), and thalamus (T) stained for PrP. O
GFP. The 22L prion-inoculated mice exhibited primarily diffuse PrP staining and extensive g
were seen in the 22L inoculated transgenic mice (open arrows), but not in mock-infected Ub
bottom panels). (C) Ubiquitin staining in sections of thalamus from UbG76V-GFP+/− mice in
seen scattered throughout the sections of the 22L prion-infected brain sections (top and b
neuron-like cells containing ubiquitin deposits that exhibit a perinuclear localization. The bot
with 22L prions demonstrates that the expression of the transgene appeared to have no effe
Disease-associated prion protein oligomers inhibit the 26S proteasome, p175–188 Copyright© ((β-PrP) [129] and semi-puriﬁed PrPSc from RML prion-infected
mouse brain. This inhibition occurred at near one to one stoichio-
metry inferring that the inhibitory species is highly potent and binds
with tight afﬁnity. The inhibitory effect on the catalytic sites was
limited to only certain aggregated β-sheet-rich conformational
isoforms of PrP [116]. Pre-incubating our β-PrP and PrPSc species
with an antibody raised against aggregation intermediates [130]
abrogated the inhibitory effect on proteolysis, suggestive of an
oligomeric inhibitory species [116]. We also used cell-based GFP-
tagged proteasome reporter substrates, and found that prion-infected
mouse neuroblastoma cells accumulated the GFP reporter indicative
of functional UPS impairment in live cells (Fig. 3A). Using a transgenic
mouse model that allows the functional status of the UPS to beoteasome reporter accumulates only in prion-infected GFP-reporter expressing N2aPK-1
K-1 cells indicating functional proteasome impairment in these cells. Cured denotes cells
rter transgenic mice (UbG76V-GFP+/−) inoculated intracerebrally with a mouse scrapie
ates inoculated with 22L prions (bottom). Left panels show low-power views of saggital
ther panels show high-power views of the thalamus stained for PrP, GFAP, and UbG76V-
liosis (black arrows point to hypertrophic astrocytes). Collections of UbG76V-GFP+ cells
G76V-GFP transgenic mice or 22L prion-infected nontransgenic littermates (middle and
oculated with 22L prions or normal brain homogenate. Ubiquitin granular deposits are
ottom panels) but rarely observed in the control (middle panel). Arrows point to large
tompanel showing a section from a UbG76V-GFP−/− nontransgenic littermate inoculated
ct on the deposition of ubiquitinated proteins. FromMolecular Cell, 26, Kristiansen et al.,
2007) with permission from Elsevier.
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speciﬁc inhibition of the UPS in these GFP-reporter transgenic mice
in vivo. We demonstrated that GFP reporter accumulation and
intracellular cytosolic granular ubiquitinated deposits occurred in
prion-infected mice only, particularly in the regions of prion-induced
neuropathology, indicative of impairment of the UPS (Fig. 3B, C)
[116]. Interestingly, the demonstration of functional proteasome
impairment in prion infection in vivo may explain earlier reports of
similar ubiquitin–protein conjugates within neurons in prion-
infected mouse brain seen early in the course of the disease [132].
Using a number of different biochemical approaches we were able to
demonstrate that oligomeric PrP species exerted their inhibitory
effects on the 20S proteasome itself [116]. Our data can be explained
mechanistically by ‘oligomeric’ PrP species having a direct inhibitory
effect on the β1 and β5 proteolytic active sites of the 20S core, but
this is unlikely due to steric hindrance as the diameter of the gated
channel is only ∼2 nm [133]. The other possible explanation is that
prions inhibit gate opening of the 20S. This second possibility is
supported by studies of gate opening where addition of hydrophobic
peptides, use of the PA28 activator, or gate deletion (which all
accelerate substrate entry) stimulate cleavage at the chymotrypsin-
like (β5) and caspase-like (β1) sites by enhancing their Vmax, but do
not stimulate the slower cleavage at the trypsin-like site (β2) [134].
Therefore, an inhibitory effect of prions on 20S gate opening would
have a more severe inhibitory effect on the chymotrypsin-like and
caspase-like activities rather than the trypsin-like site—an effect seen
in our published data [116] and further supported by our current
work (Deriziotis et al., unpublished data). Other key questions that
arise from this work are the route whereby misfolded forms of
disease-associated PrP enter the cytosol, and the role of other
degradation pathways, such as autophagy, in prion pathogenesis.
2.4. Autophagy and other pathways in prion protein clearance
In neurodegenerative disease, abnormal proteins with aberrant
conformations often aggregate into inclusions. Autophagy, the bulk
degradation of cytoplasmic proteins and organelles, may be the
principal clearance mechanism by which cells degrade diffuse or
oligomeric protein [135]. Induction of autophagy enhances expanded
polyQ and α-synuclein clearance in cell models [136], and has been
shown to attenuate the toxicity of mutant huntingtin fragments, and
both mutant and wild-type tau [137,138]. Autophagy is not well
characterised in prion disease. Evidence of autophagy in prion disease
is limited to EM showing autophagosomes in experimental models of
scrapie, and in human CJD and GSS [139], suggesting it may play a role
in intracellular prion protein clearance.
Understanding prion protein clearance mechanisms in prion
disease is clearly important in understanding aspects of pathogenesis.
Apart from autophagy, which may play a role in clearance,
extracellular prion protein clearance by microglia has recently been
demonstrated [140]. Glial cells, such as microglia, do not replicate
prions [141], even though microglia activation has been documented
in prion disease [142]. Interestingly, however, when prion organotypic
slice culture assays (POSCA) are depleted of microglia they a)
accumulate high levels of PrPSc, b) have 15 fold higher prion titers
and c) are more susceptible to infection when compared to microglia-
containing slices [140]. Microglia may indeed have an important role
in controlling prion infection by clearing misfolded prions via
phagocytosis.
3. Concluding remarks
Whilst prion infection causes widespread neuronal loss in the
brain, the molecular basis of prion neurotoxicity is not understood.
Neurodegeneration cannot be explained by a loss of functional
PrPC, as its depletion does not trigger any gross pathology. Thealternative explanation, that PrPSc itself is directly neurotoxic, does
not adequately explain many observations where neurons can be
in close proximity to PrPSc deposits without suffering deleterious
effects.
The pathogenesis of prion disease is likely to be multifactorial, but
the potent inhibition of the proteasome by pathogenic PrP may result
in neuronal perturbation and contribute to the widespread neuronal
loss. It is not yet clear whether proteasome impairment is a primary or
secondary event (due to upstream cellular dysfunction) in prion
disease pathophysiology, and work is ongoing to try and clarify this.
Proteasome inhibition by prions also explains how cytosolic aggre-
gated forms of PrPC may accumulate in prion disease, with UPS
inhibition leading to the cytosolic accumulation of PrPC destined for
ER-associated degradation. Impairment of the UPS leads to cellular
dysfunction and apoptosis throughmany different mechanisms, as the
UPS is also involved in transcriptional regulation, cell cycle control,
and control of apoptosis [82]. Given the signiﬁcant role that has
emerged for the UPS in protein-misfolding disorders combined with
the age-dependent decrease in UPS activity, designing drugs that
improve neuronal UPS function may offer a successful intervention to
slow or prevent neurodegenerative diseases in which toxic proteins
are misfolded.
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